title: The risk of peripheral vein phlebitis associated with chlorhexidine-coated catheters: a randomized, double-blind trial.
abstract: OBJECTIVE
  To evaluate the risk of phlebitis associated with chlorhexidine-coated polyurethane catheters in peripheral veins.
  
  
  METHODS
  A randomized, double-blinded trial comparing chlorhexidine-coated polyurethane catheters with uncoated polyurethane catheters.
  
  
  METHODS
  A university hospital.
  
  
  METHODS
  Adult medicine and surgery patients.
  
  
  METHODS
  Certified registered nurse anesthetists or an infusion team consisting of nurses and physicians inserted the catheters. Catheter insertion sites were scored twice daily for evidence of phlebitis. At the time catheters were removed, a quantitative blood culture was performed, and catheters were sonicated for quantitative culture.
  
  
  RESULTS
  Of 221 evaluable catheters, phlebitis developed in 18 (17%) of 105 coated catheters, compared to 27 (23%) of 116 uncoated catheters (relative risk [RR], 0.74; 95% confidence interval [CI95], 0.43-1.26; P = .32). By survival analysis, chlorhexidine-coated catheters had a lower risk of phlebitis during the first 3 days (P = .06), but not when all catheters were considered in both patient groups (P = .31). In the absence of catheter colonization, the incidence of phlebitis was 21% (16/76) and 24% (20/86) for coated and uncoated catheters, respectively (P = .85), whereas in the presence of catheter colonization, the incidence of phlebitis was 14% (1/7) and 80% (4/5) for coated and uncoated catheters, respectively (RR, 0.18; CI95, 0.03-1.15; P = .07).
  
  
  CONCLUSIONS
  The risk of phlebitis in the presence of catheter colonization was 82% lower for chlorhexidine-coated polyurethane catheters compared to otherwise identical uncoated catheters.
authors.affiliation: Department of Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27157-1042, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Sherertz
authors.forename: J L
authors.initials: JL
authors.lastname: Stephens
authors.forename: R D
authors.initials: RD
authors.lastname: Marosok
authors.forename: W A
authors.initials: WA
authors.lastname: Carruth
authors.forename: H A
authors.initials: HA
authors.lastname: Rich
authors.forename: K D
authors.initials: KD
authors.lastname: Hampton
authors.forename: S M
authors.initials: SM
authors.lastname: Motsinger
authors.forename: L C
authors.initials: LC
authors.lastname: Harris
authors.forename: P E
authors.initials: PE
authors.lastname: Scuderi
authors.forename: J G
authors.initials: JG
authors.lastname: Pappas
authors.forename: S C
authors.initials: SC
authors.lastname: Felton
authors.forename: D D
authors.initials: DD
authors.lastname: Solomon
mesh_terms: D000328:Adult; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage*; D002406:Catheterization, Peripheral / Q000009:adverse effects* / Q000379:methods; D002408:Catheters, Indwelling / Q000009:adverse effects / Q000382:microbiology*; D002710:Chlorhexidine / Q000008:administration & dosage*; D016001:Confidence Intervals; D003428:Cross Infection / Q000517:prevention & control*; D004311:Double-Blind Method; D004866:Equipment Contamination / Q000517:prevention & control*; D005260:Female; D006801:Humans; D017053:Infection Control / Q000379:methods / Q000592:standards; D008297:Male; D010689:Phlebitis / Q000517:prevention & control*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012306:Risk; D018401:Sample Size; D013210:Staphylococcus / Q000302:isolation & purification; D016019:Survival Analysis
chemical_list: D000891:Anti-Infective Agents, Local; D002710:Chlorhexidine